“De novo” is a Latin phrase meaning “from the beginning” or “from new.” It describes something that arises fresh, without being derived from or built upon anything that came before. You’ll encounter this term most often in genetics, biology, medicine, and law, where it carries slightly different but related meanings depending on the context.
De Novo Mutations in Genetics
The most common use of “de novo” in science refers to genetic mutations that appear in a child but aren’t present in either parent. These aren’t inherited in the traditional sense. Instead, they arise spontaneously, either in a parent’s egg or sperm cell before conception or during the earliest cell divisions after fertilization. When a doctor tests a child’s blood and finds a variant, then tests both parents and finds neither carries it, that variant is classified as de novo.
Every person is born with roughly 61 new single-letter changes in their DNA that neither parent had. Most of these fall in non-coding regions of the genome (the vast stretches of DNA that don’t directly build proteins) and have no noticeable effect. A smaller number land in protein-coding regions, where they’re more likely to matter. The mutation rate in and near these coding regions is somewhat higher than the genome-wide average, partly because of the chemical composition of those stretches of DNA.
About 10% of what initially look like straightforward de novo mutations actually arose not in a single parental egg or sperm but during the very first cell divisions of the embryo itself. These are called “gonosomal” variants, and they can show up in both the child’s body tissues and reproductive cells. This distinction matters because it affects the chance of the same mutation appearing in a future sibling.
How Paternal Age Plays a Role
Sperm cells divide continuously throughout a man’s life, and each division is an opportunity for a copying error. Egg cells, by contrast, are mostly formed before a woman is born. This means the number of de novo mutations in a child’s DNA correlates more strongly with the father’s age at conception. Research published in Nature Communications found that the risk of autism spectrum disorder associated with advanced paternal age was roughly 9.3 times greater than what could be explained by de novo DNA changes alone, suggesting that paternal age influences disease risk through additional biological mechanisms beyond simple mutation accumulation.
How Doctors Confirm a De Novo Variant
The standard approach is called trio testing. A clinical lab sequences the DNA of the child (the “proband”) and both biological parents simultaneously. By comparing all three, geneticists can pinpoint variants present in the child but absent from both parents. In one large study of families with kidney and urinary tract abnormalities, trio analysis identified strong de novo variants in about 20% of cases, leading to the discovery of dozens of new candidate genes for those conditions. This trio approach has become a cornerstone of diagnosing rare genetic disorders, especially when a child’s condition doesn’t match any known inherited pattern in the family.
De Novo in Biochemistry
In biochemistry, “de novo” describes any process where the body builds a complex molecule from scratch using simple building blocks, rather than recycling pre-existing components.
One well-known example is de novo lipogenesis, the process by which your liver converts excess carbohydrates into fat. When you consume more sugar or starch than your body needs for immediate energy, liver cells break glucose (and especially fructose) down into small two-carbon units and then stitch those units together into fatty acid chains. This is why diets very high in sugar can contribute to fatty liver disease even without high dietary fat intake.
Another example is de novo purine synthesis, the way cells build the molecular letters of DNA and RNA from amino acids, carbon dioxide, and other small molecules. This pathway requires 10 chemical steps and burns through 6 molecules of ATP (the cell’s energy currency) for every purine it produces. Cells also have a “salvage” pathway that recycles purines from broken-down DNA, costing only 1 ATP per molecule. The body uses both systems depending on demand, but rapidly dividing cells, like immune cells or cancer cells, rely heavily on the energy-expensive de novo route.
De Novo Drug Design
In pharmaceutical research, de novo drug design means creating entirely new drug molecules from atomic or molecular building blocks rather than screening through libraries of existing compounds. Computational algorithms assemble candidate molecules piece by piece, evaluating each one for how well it might fit a target protein on a cell’s surface.
There are two main strategies. Atom-based methods explore an enormous range of possible structures by adding one atom at a time, then filter the results for molecules that could realistically be manufactured and absorbed by the body. Fragment-based methods start with small molecular pieces known to interact with the target and connect them with chemical linkers, producing candidates that tend to be more practical to synthesize. More recently, deep learning tools, including neural networks and reinforcement learning, have accelerated this process by predicting which molecular shapes are most likely to work before any lab testing begins.
De Novo Protein Design
A related frontier is de novo protein design: engineering proteins with specific three-dimensional shapes and functions that don’t exist anywhere in nature. The challenge is staggering because the number of possible amino acid sequences grows exponentially with each added building block. Traditional approaches involve assembling known structural fragments into a desired shape, then computationally searching for a sequence that would fold into it. This method has already produced novel protein architectures, including barrel-shaped and jellyroll-shaped structures never seen in natural organisms.
The field has accelerated with deep learning tools like AlphaFold, which can predict how a protein sequence will fold. Researchers now run this process in reverse: they start with a target shape and use AI to generate sequences predicted to fold into it. Validated designs typically show a water-attracting surface and a tightly packed water-repelling core, the hallmarks of a stable, well-folded protein.
De Novo Resistance in Cancer Treatment
In oncology, “de novo resistance” (also called primary resistance) means a tumor never responds to a given treatment from the very first dose. This is distinct from acquired resistance, where a treatment initially shrinks or controls the cancer but the tumor eventually grows back because resistant cells survive and repopulate. The distinction matters for treatment planning: de novo resistance signals that the doctor needs to switch strategies entirely, while acquired resistance may call for adding a second agent or adjusting the existing regimen.
De Novo in Law
Outside of science, you’ll most commonly see “de novo” in legal contexts. A “de novo review” or “trial de novo” means a higher court re-examines a case from scratch, as if the lower court’s decision never happened. The judge considers all the evidence fresh, rather than simply checking whether the original court made a procedural error. This gives both sides a complete do-over before a new decision-maker.